CLAIMS

1. A vaccine composition comprising an influenza virus peptide comprising a CD8+ T cell epitope and an influenza virus peptide comprising a B cell epitope, wherein each peptide is attached to a nanoparticle.

2. The vaccine composition of claim 1, wherein the nanoparticle is a gold nanoparticle, a calcium phosphate nanoparticle, or a silicon nanoparticle.

3. The vaccine composition of claim 1 or 2, wherein the influenza virus peptide comprising a CD8+ T cell epitope and the influenza virus peptide comprising a B cell epitope are attached to the same nanoparticle.

4. The vaccine composition of any one of the preceding claims, wherein the influenza virus peptide comprising a CD8+ T cell epitope is attached to the nanoparticle via a linker and /or the influenza virus peptide comprising a B cell epitope is attached to the nanoparticle via a linker.

5. The vaccine composition of any one of the preceding claims, wherein the influenza virus peptide comprising a CD8+ T cell epitope comprises one or more of the peptides set out in SEQ ID NOs: 1 to 21.

6. The vaccine composition of any one of the preceding claims, wherein the B cell epitope is an influenza matrix 2 protein (M2e) epitope.

7. A vaccine composition comprising an influenza virus peptide comprising one or more of the CD8+ T cell epitopes set out in SEQ ID NOs: 1 to 21, wherein the peptide is attached to a nanoparticle.

8. The vaccine composition of claim 7, wherein the nanoparticle is a gold nanoparticle, a calcium phosphate nanoparticle, or a silicon nanoparticle.

9. The vaccine composition of claim 8, wherein the influenza virus peptide comprising a CD8+ T cell epitope is attached to the nanoparticle via a linker.

10. The vaccine composition of any one of the preceding claims, which comprises two or more influenza virus peptides each comprising a different CD8+ T cell epitope.

11. The vaccine composition of claim 10, wherein the two or more influenza virus peptides are two or more of the peptides set out in SEQ ID NOs: 1 to 21.

12. The vaccine composition of any one of the preceding claims, further comprising an influenza virus peptide comprising a CD4+ T cell epitope.

13. The vaccine composition of claim 12, wherein the influenza virus peptide comprising a CD4+ T cell epitope is attached to a nanoparticle.

14. The vaccine composition of claim 13, wherein the nanoparticle to which the influenza virus peptide comprising a CD4+ T cell epitope is attached is a gold nanoparticle, a calcium phosphate nanoparticle, or a silicon nanoparticle.

15. The vaccine composition of claim 13 or 14, wherein the influenza virus peptide comprising a CD4+ T cell epitope is attached to the nanoparticle via a linker.

16. The vaccine composition of any one of the preceding claims, wherein the influenza virus peptide comprising a CD8+ T cell epitope further comprises a CD4+ T cell epitope.

17. The vaccine composition of claim 16, wherein the influenza virus peptide comprising a CD8+ T cell epitope and a CD4+ T cell epitope comprises one or more of the peptides set out in SEQ ID NOs: 22 to 27.

18. The vaccine composition of any one of the preceding claims, comprising at least two influenza virus peptides comprising a CD8+ T cell epitope which each interacts with a different HLA supertype.

19. The vaccine composition of any one of the preceding claims, which comprises at least one immunogenic peptide that interacts with at least two different HLA supertypes.

20. The vaccine composition of claim 18 or 19, wherein the at least two different HLA supertypes are selected from HLA-A1, HLA-A2, HLA-A3, HLA-A24, HLA-B7, HLA-B8, HLA-B27, HLA-B44, HLA-B58 and HLA-B62.

21. The vaccine composition of claim 20, wherein the at least two different HLA supertypes are HLA-A2 and HLA-A24.

22. A method of preventing or treating an influenza virus infection, comprising administering the vaccine composition of any one of the preceding claims to an individual infected with, or at risk of being infected with, an influenza virus.

23. The method of claim 22, wherein the influenza virus is a pandemic influenza virus.

24. The vaccine composition of any one of claims 1 to 21 for use in a method of preventing or treating an influenza virus infection in an individual.

25. The vaccine composition for use according to claim 24, wherein the influenza virus is a pandemic influenza virus.